Expression of the apoptosis suppressing bcl-2 protein in transitional cell bladder tumours

Histopathology

Volumn 28, Issue 2, 1996, Pages 135-140

  Lipponen, P K ^a   Aaltomaa, S ^a   Eskelinen, M ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

bcl 2; Bladder tumour; Transitional epithelium

Indexed keywords

ENDOGENOUS COMPOUND; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

EID: 0030049850     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1996.276322.x     Document Type: Article

References (26)

1. Zingg EJ, Wallace DMA. Bladder cancer. Heidelberg: Springer-Verlag, 1985; 1-21, 161-191.
2. Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R, Haapasalo H. Independent clinical, histological and quantitative prognostic factors in transitional-cell bladder tumours, with special reference to mitotic frequency. Int. J. Cancer. 1992; 51; 396-403.
3. Hockenbery DM. The bcl-2 oncogene and apoptosis. Semin. Immunol. 1992; 4; 413-420.
4. Allan DJ, Howell A, Roberts SA et al. Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. J. Pathol. 1991; 163; 337-342.
5. Wyllie AH. Apoptosis and the regulation of cell numbers of normal and neoplastic tissues: a overview. Cancer Metast. Rev. 1992; 11; 95-103.
6. Castle VP, Heidelberger KP, Bromberg J, Ou X, Dole M, Nunez G. Expression of apoptosis-suppressing proteien bcl-2 in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am. J. Pathol. 1993; 143; 1543-1550.
7. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and it's prognostic value. Int. J. Cancer. 1993; 53; 365-370.
8. Lipponen P. Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur. J. Cancer 1993; 29A; 749-753.
9. Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br. J. Cancer 1994; 69; 1120-1125.
10. Soini Y, Turpeenniemi-Hujanen T, Kamel D et al. p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br. J. Cancer 1995; 68; 1029-1035.
11. Cordon-Cardo C, Wartinger D, Petrylak D et al. Altered expression of retinoblastoma gene product: prognostic indicator in bladder cancer. J. Natl. Canrer Inst. 1992; 84; 1251-1256.
12. Sarkis AS, Dalbagni G, Cordon-Cardo C et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: A marker for disease progression. J. Natl. Cancer Inst. 1995; 85; 53-59.
13. Lipponen PK, Nordling S, Eskelinen MJ, Jauhiainen K, Terho R, Harju E. Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional-cell bladder cancer. Int. J. Cancer 1993; 53; 42-47.
14. International Union Against Cancer (UIC). TNM classification of malignant tumours. Geneva: UICC, 1978.
15. Mostofi FK. International histological classification of tumours. In No 10 Histological typing of urinary bladder tumours. Geneva: WHO, 1973.
16. Lipponen P, Aaltomaa S. Apoptosis in transitional cell bladder cancer as related to standard prognostic factors and prognosis. J. Pathol. 1994; 173; 333-339.
17. Shi S-R, Key ME, Kalra KL. Antigen retrieval in formalin-fixed paraffin-embedded tissues. An enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem. 1991; 39; 741-748.
18. Lee E, Desu M. A computer program for comparing k samples with right censored data. Comput. Prog. Biomed. 1972; 2; 315-318.
19. Schena M, Gottardi D, Chia P et al. The role of bcl-2 in the pathogenesis of B chronic lymphocytic leukemia. Leuk. Lymphoma 1993; 11; 173-179.
20. Sachs L, Lotem J. Control of programmed cell death in normal and leucemic cells: new implications for therapy. Blood 1993; 82; 15-21.
21. Hollowood K, Macartney JC. Reduced apoptotic cell death in follicular lymphoma. J. Pathol. 1991; 163; 337-342.
22. Wangg Y, Szekely L, Okan I, Klein G, Wiman KG. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 1993; 8; 3427-3431.
23. Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of bcl-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference oestrogen receptor status. Virchows Archiv. 1994; 424; 47-51.
24. Doussis IA, Pezzella F, Lane DP, Gatter KC, Mason DY. An immunocytochemical study of p53 and bcl-2 protein expression in Hodkins disease. Am. J. Clin. Pathol. 1993; 99; 663-667.
25. Silvestrini R, Veneroni S, Daidone MG et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl. Cancer Inst. 1994; 86; 499-504.
26. Leoncini L, Del-Vecchio MT, Megha T et al. Correlations between apoptotic and proliferative indices in malignant non-Hodkins lymphomas. Am. J. Pathol. 1993; 142; 755-763.